What Is Rallybio Corporation (RLYB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Rallybio Corporation's intrinsic value is estimated at $8.76, suggesting the stock is overvalued at its current price of $16.13. With 7 out of 9 models flagging downside (-45.7% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at -2.2% (fair value: $15.78), while ML-RIV is the most conservative at -97.2% ($0.45). The spread between these extremes — +95.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About RLYB?
9 of 13 models are currently active for RLYB. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates RLYB's intrinsic value at $8.14, implying -49.5% downside from the current price. See which stocks rank higher →
How Does RLYB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RLYB ranks #163 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Rallybio Corporation operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating RLYB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is RLYB a Value Trap?
CirclFi's Value Trap algorithm assigns RLYB a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Rallybio Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Rallybio Corporation's fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +95.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RLYB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RLYB's 9 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad